
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News / Financial</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Mon, 21 Jul 2008 07:49:43 CEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[Novartis gains momentum with strong performance in first half of 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_gains_momentum_with_strong_performance_in_first_half_of_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_gains_momentum_with_strong_performance_in_first_half_of_2008/</comments>
<pubDate>Mon, 21 Jul 2008 07:49:43 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_gains_momentum_with_strong_performance_in_first_half_of_2008/</guid>
<description><![CDATA[- First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics- Net sales rise 11% (+2% in local currenc<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Reports_Stronger-than-Expected_Sales_and_Earnings_Growth_in_Second_Quarter/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Reports_Stronger-than-Expected_Sales_and_Earnings_Growth_in_Second_Quarter/</comments>
<pubDate>Fri, 18 Jul 2008 00:22:26 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Reports_Stronger-than-Expected_Sales_and_Earnings_Growth_in_Second_Quarter/</guid>
<description><![CDATA[Based on the company's strong performance year-to-date, and the outlook for the remainder of the year, Abbott is raising both its sales growth and earnings-per-share forecasts for the full-year 2008<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis completes acquisition of 25% stake in Alcon from Nestl]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_completes_acquisition_of_25_stake_in_Alcon_from_Nestl%E9/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_completes_acquisition_of_25_stake_in_Alcon_from_Nestl%E9/</comments>
<pubDate>Thu, 10 Jul 2008 00:12:24 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_completes_acquisition_of_25_stake_in_Alcon_from_Nestl%E9/</guid>
<description><![CDATA[Novartis has acquired a 25% stake in Alcon Inc. (NYSE: ACL) as part of a definitive agreement with Nestlé S.A. reached in April 2008 that provides the right to acquire majority ownership of the world<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Shire proposes acquisition of Jerini AG for an equity purchase price of 328 million]]></title>
<link>http://www.worldpharmanews.net/Financial/Shire_proposes_acquisition_of_Jerini_AG_for_an_equity_purchase_price_of_%C2%80328_million/</link>
<comments>http://www.worldpharmanews.net/Financial/Shire_proposes_acquisition_of_Jerini_AG_for_an_equity_purchase_price_of_%C2%80328_million/</comments>
<pubDate>Sun, 06 Jul 2008 09:06:49 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Shire_proposes_acquisition_of_Jerini_AG_for_an_equity_purchase_price_of_%C2%80328_million/</guid>
<description><![CDATA[Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed &quot;Shire Deutschland Investments GmbH&quot;, a G<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche's tender offer to increase ownership stake in Chugai successful]]></title>
<link>http://www.worldpharmanews.net/Financial/Roches_tender_offer_to_increase_ownership_stake_in_Chugai_successful/</link>
<comments>http://www.worldpharmanews.net/Financial/Roches_tender_offer_to_increase_ownership_stake_in_Chugai_successful/</comments>
<pubDate>Fri, 27 Jun 2008 00:14:49 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roches_tender_offer_to_increase_ownership_stake_in_Chugai_successful/</guid>
<description><![CDATA[Roche announced that its ownership stake in Chugai will increase from 50.1% to 59.9% following the successful completion of the tender offer which started on 23 May. Chugai shareholders had the oppor<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_of_Encysive_Pharmaceuticals_Inc-/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_of_Encysive_Pharmaceuticals_Inc-/</comments>
<pubDate>Fri, 13 Jun 2008 09:34:02 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Completes_Acquisition_of_Encysive_Pharmaceuticals_Inc-/</guid>
<description><![CDATA[Pfizer Inc (NYSE:PFE) announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) through a merger of Pfizer's w<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc.]]></title>
<link>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_acquires_Sirtris_Pharmaceuticals_Inc-/</link>
<comments>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_acquires_Sirtris_Pharmaceuticals_Inc-/</comments>
<pubDate>Tue, 10 Jun 2008 00:05:03 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_acquires_Sirtris_Pharmaceuticals_Inc-/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) announced that it has completed its acquisition of Sirtris Pharmaceuticals, Inc. (Sirtris) for approximately USD720 million (or approx. GBP362 million) through a cash tender off<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[A promising start into 2008 for Nycomed]]></title>
<link>http://www.worldpharmanews.net/Financial/A_promising_start_into_2008_for_Nycomed/</link>
<comments>http://www.worldpharmanews.net/Financial/A_promising_start_into_2008_for_Nycomed/</comments>
<pubDate>Thu, 22 May 2008 00:03:03 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/A_promising_start_into_2008_for_Nycomed/</guid>
<description><![CDATA[In the first quarter of 2008, Nycomed's adjusted EBITDA increased by 6.2% to € 304.0 million compared to € 286.3 million in the first quarter of 2007, benefiting from the cost decreasing effects of l<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals]]></title>
<link>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</link>
<comments>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</comments>
<pubDate>Tue, 06 May 2008 00:09:56 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_commences_tender_offer_to_acquire_Sirtris_Pharmaceuticals/</guid>
<description><![CDATA[GlaxoSmithKline plc (GSK) announced that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Si<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Esperion Therapeutics Completes $22.75 M Series A Financing]]></title>
<link>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</link>
<comments>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</comments>
<pubDate>Fri, 02 May 2008 00:06:06 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Esperion_Therapeutics_Completes_22-75_M_Series_A_Financing/</guid>
<description><![CDATA[Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today announced that it has been l<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12]]></title>
<link>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</link>
<comments>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</comments>
<pubDate>Mon, 28 Apr 2008 12:30:33 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Amgens_First_Quarter_2008_Adjusted_Earnings_Per_Share_Increased_4_percent_to_1-12/</guid>
<description><![CDATA[Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the first quarter of 2008, an increase of 4 percent compared to<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca PLC First Quarter Results 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_First_Quarter_Results_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_First_Quarter_Results_2008/</comments>
<pubDate>Sat, 26 Apr 2008 00:01:40 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/AstraZeneca_PLC_First_Quarter_Results_2008/</guid>
<description><![CDATA[Sales in the first quarter increased by 4 percent at CER, or 10 percent on an as reported basis. Sales in the US were up 5 percent; the inclusion of MedImmune sales in the quarter more than offset th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Reports Strong First-Quarter Growth]]></title>
<link>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Strong_First-Quarter_Growth/</link>
<comments>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Strong_First-Quarter_Growth/</comments>
<pubDate>Fri, 25 Apr 2008 00:04:10 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Genzyme_Reports_Strong_First-Quarter_Growth/</guid>
<description><![CDATA[Genzyme Corporation (NASDAQ: GENZ) reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, an<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis reports higher sales and earnings in first quarter of 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_reports_higher_sales_and_earnings_in_first_quarter_of_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_reports_higher_sales_and_earnings_in_first_quarter_of_2008/</comments>
<pubDate>Fri, 25 Apr 2008 00:04:00 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_reports_higher_sales_and_earnings_in_first_quarter_of_2008/</guid>
<description><![CDATA[On track for solid growth in 2008, Novartis reported higher net sales and double-digit earnings growth in the first quarter of 2008 from the Group's continuing operations now entirely focused on hea<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The Medicines Company Reports First Quarter 2008 Financial Results]]></title>
<link>http://www.worldpharmanews.net/Financial/The_Medicines_Company_Reports_First_Quarter_2008_Financial_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/The_Medicines_Company_Reports_First_Quarter_2008_Financial_Results/</comments>
<pubDate>Thu, 24 Apr 2008 00:05:18 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/The_Medicines_Company_Reports_First_Quarter_2008_Financial_Results/</guid>
<description><![CDATA[The Medicines Company (NASDAQ: MDCO) today announced its financial results for the first quarter of 2008. Financial highlights for the first quarter of 2008<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Reports First-Quarter 2008 Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2008_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2008_Results/</comments>
<pubDate>Sat, 19 Apr 2008 00:07:18 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Reports_First-Quarter_2008_Results/</guid>
<description><![CDATA[Pfizer Inc (NYSE: PFE) reported results for the first-quarter 2008. The Company recorded revenues of $11.8 billion, a decrease of 5% compared with $12.5 billion in the year-ago quarter, primarily due<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter]]></title>
<link>http://www.worldpharmanews.net/Financial/Abbott_Reports_Double-Digit_Sales_and_Earnings_Growth_in_First_Quarter/</link>
<comments>http://www.worldpharmanews.net/Financial/Abbott_Reports_Double-Digit_Sales_and_Earnings_Growth_in_First_Quarter/</comments>
<pubDate>Fri, 18 Apr 2008 00:10:16 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Abbott_Reports_Double-Digit_Sales_and_Earnings_Growth_in_First_Quarter/</guid>
<description><![CDATA[Abbott (NYSE: ABT) announced financial results for the first quarter ended March 31, 2008. Diluted earnings per share, excluding specified items, were $0.63, reflecting 14.5 percent growth, at the up<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche fully acquires privately-owned biotech company Piramed]]></title>
<link>http://www.worldpharmanews.net/Financial/Roche_fully_acquires_privately-owned_biotech_company_Piramed/</link>
<comments>http://www.worldpharmanews.net/Financial/Roche_fully_acquires_privately-owned_biotech_company_Piramed/</comments>
<pubDate>Thu, 17 Apr 2008 00:05:19 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roche_fully_acquires_privately-owned_biotech_company_Piramed/</guid>
<description><![CDATA[Roche announced that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI3-kinase (PI3-K). The PI3-K pathway is known to play an important role in disea<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis to first acquire 25% stake from Nestl for USD 143.18 per share for USD 11 billion]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_to_first_acquire_25_stake_from_Nestl%E9_for_USD_143-18_per_share_for_USD_11_billion/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_to_first_acquire_25_stake_from_Nestl%E9_for_USD_143-18_per_share_for_USD_11_billion/</comments>
<pubDate>Wed, 09 Apr 2008 00:04:38 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_to_first_acquire_25_stake_from_Nestl%E9_for_USD_143-18_per_share_for_USD_11_billion/</guid>
<description><![CDATA[Novartis has reached an agreement with Nestlé S.A. providing the right to acquire majority ownership of Alcon Inc. (NYSE: ACL) in two steps and add the world leader in eye care to its diversified por<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche raises dividend by 35 percent]]></title>
<link>http://www.worldpharmanews.net/Financial/Roche_raises_dividend_by_35_percent/</link>
<comments>http://www.worldpharmanews.net/Financial/Roche_raises_dividend_by_35_percent/</comments>
<pubDate>Tue, 08 Apr 2008 00:19:40 CEST</pubDate>
<dc:creator>Roche</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Roche_raises_dividend_by_35_percent/</guid>
<description><![CDATA[Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 662 shareholders in attendance, representing 143,480,308, or 89.7% of a total <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Successfully_Completes_Tender_Offer_for_Shares_of_Encysive_Pharmaceuticals_Inc-/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Successfully_Completes_Tender_Offer_for_Shares_of_Encysive_Pharmaceuticals_Inc-/</comments>
<pubDate>Wed, 02 Apr 2008 00:20:49 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Successfully_Completes_Tender_Offer_for_Shares_of_Encysive_Pharmaceuticals_Inc-/</guid>
<description><![CDATA[Pfizer Inc (NYSE:PFE) announced that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has purchased all of the shares validly tendered and not withdrawn pursuant to its tender offer f<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[BBC NEWS | Lehman to sue over Japan 'fraud']]></title>
<link>http://www.worldpharmanews.net/Financial/BBC_NEWS__Lehman_to_sue_over_Japan_fraud/</link>
<comments>http://www.worldpharmanews.net/Financial/BBC_NEWS__Lehman_to_sue_over_Japan_fraud/</comments>
<pubDate>Mon, 31 Mar 2008 14:41:59 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/BBC_NEWS__Lehman_to_sue_over_Japan_fraud/</guid>
<description><![CDATA[The US giant is seeking to recoup $350m (£175m) from Marubeni over loans given through Marubeni to a now bankrupt medical company called Asclepius.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  US Rx Sales Grew Just 3.8 Percent In 'O7]]></title>
<link>http://www.worldpharmanews.net/Financial/Pharmalot_-_US_Rx_Sales_Grew_Just_3-8_Percent_In_O7/</link>
<comments>http://www.worldpharmanews.net/Financial/Pharmalot_-_US_Rx_Sales_Grew_Just_3-8_Percent_In_O7/</comments>
<pubDate>Thu, 13 Mar 2008 00:30:57 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pharmalot_-_US_Rx_Sales_Grew_Just_3-8_Percent_In_O7/</guid>
<description><![CDATA[Total US dispensed prescription volume grew at a 2.8 percent pace, compared with 4.6 percent in 2006, with antidepressants ranked as the leading therapy class. Overall, the top five therapeutic categ<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[A successful 2007 paves the way for future of Nycomed]]></title>
<link>http://www.worldpharmanews.net/Financial/A_successful_2007_paves_the_way_for_future_of_Nycomed/</link>
<comments>http://www.worldpharmanews.net/Financial/A_successful_2007_paves_the_way_for_future_of_Nycomed/</comments>
<pubDate>Tue, 11 Mar 2008 00:28:53 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/A_successful_2007_paves_the_way_for_future_of_Nycomed/</guid>
<description><![CDATA[In 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last year to a total of € 1,222.2 million. The strong performance was accompanied in the fourth quarter by major advancements in the US <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[DAIICHI SANKYO acquires osteoporosis medication EVISTA from Lilly]]></title>
<link>http://www.worldpharmanews.net/Financial/DAIICHI_SANKYO_acquires_osteoporosis_medication_EVISTA%AE_from_Lilly/</link>
<comments>http://www.worldpharmanews.net/Financial/DAIICHI_SANKYO_acquires_osteoporosis_medication_EVISTA%AE_from_Lilly/</comments>
<pubDate>Sat, 08 Mar 2008 12:39:02 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/DAIICHI_SANKYO_acquires_osteoporosis_medication_EVISTA%AE_from_Lilly/</guid>
<description><![CDATA[The Japanese pharmaceutical company DAIICHI SANKYO Group has purchased the European rights to the osteoporosis medication EVISTA® from the U.S. Company Eli Lilly and Company. In the process, the comp<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer Analyst Day: The Analysts React  - Pharmas Market with Mike Huckman - MSNBC.com]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_Analyst_Day_The_Analysts_React__-_Pharmas_Market_with_Mike_Huckman_-_MSNBC-com/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_Analyst_Day_The_Analysts_React__-_Pharmas_Market_with_Mike_Huckman_-_MSNBC-com/</comments>
<pubDate>Fri, 07 Mar 2008 00:17:07 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_Analyst_Day_The_Analysts_React__-_Pharmas_Market_with_Mike_Huckman_-_MSNBC-com/</guid>
<description><![CDATA[Pfizer held its analyst day yesterday and the stock closed at a new multi-year low. This morning the shares are under a little bit of pressure again as analyst reaction to the event pours in.In a<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pharmalot  Drug Prices Rose 7.4 Percent On Widely Used Meds]]></title>
<link>http://www.worldpharmanews.net/Financial/Pharmalot_-_Drug_Prices_Rose_7-4_Percent_On_Widely_Used_Meds/</link>
<comments>http://www.worldpharmanews.net/Financial/Pharmalot_-_Drug_Prices_Rose_7-4_Percent_On_Widely_Used_Meds/</comments>
<pubDate>Wed, 05 Mar 2008 01:08:08 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pharmalot_-_Drug_Prices_Rose_7-4_Percent_On_Widely_Used_Meds/</guid>
<description><![CDATA[AARP's Public Policy Institute finds that price increases for brand name drugs have far outstripped the price increases for other consumer goods and services between 2002 and 2007; this is consisten<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[ADRs in Focus: Novartis ADRs decline - MSNBC Wire Services]]></title>
<link>http://www.worldpharmanews.net/Financial/ADRs_in_Focus_Novartis_ADRs_decline_-_MSNBC_Wire_Services/</link>
<comments>http://www.worldpharmanews.net/Financial/ADRs_in_Focus_Novartis_ADRs_decline_-_MSNBC_Wire_Services/</comments>
<pubDate>Mon, 03 Mar 2008 00:06:24 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/ADRs_in_Focus_Novartis_ADRs_decline_-_MSNBC_Wire_Services/</guid>
<description><![CDATA[Shares of Swiss drug maker Novartis AG fell Friday after an HSBC analyst downgraded the stock on concerns that generic competition will stunt Novartis' profit and revenue growth. HSBC analyst Kevin <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[The Bayer Group once again considerably improved its sales and earnings in 2007]]></title>
<link>http://www.worldpharmanews.net/Financial/The_Bayer_Group_once_again_considerably_improved_its_sales_and_earnings_in_2007/</link>
<comments>http://www.worldpharmanews.net/Financial/The_Bayer_Group_once_again_considerably_improved_its_sales_and_earnings_in_2007/</comments>
<pubDate>Fri, 29 Feb 2008 00:36:42 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/The_Bayer_Group_once_again_considerably_improved_its_sales_and_earnings_in_2007/</guid>
<description><![CDATA[The Bayer Group once again considerably improved its sales and earnings in 2007, and also exceeded its performance targets. &quot;2007 was Bayer's most successful year to date,&quot; said Management Board C<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Shire plc accelerating new product sales drive revenue growth of 36%]]></title>
<link>http://www.worldpharmanews.net/Financial/Shire_plc_accelerating_new_product_sales_drive_revenue_growth_of_36/</link>
<comments>http://www.worldpharmanews.net/Financial/Shire_plc_accelerating_new_product_sales_drive_revenue_growth_of_36/</comments>
<pubDate>Fri, 22 Feb 2008 23:29:19 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Shire_plc_accelerating_new_product_sales_drive_revenue_growth_of_36/</guid>
<description><![CDATA[Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 - a year which has seen significant growth in launched <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results]]></title>
<link>http://www.worldpharmanews.net/Financial/Onyx_Pharmaceuticals_Reports_Fourth_Quarter_and_Twelve-Month_2007_Financial_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/Onyx_Pharmaceuticals_Reports_Fourth_Quarter_and_Twelve-Month_2007_Financial_Results/</comments>
<pubDate>Wed, 20 Feb 2008 00:08:36 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Onyx_Pharmaceuticals_Reports_Fourth_Quarter_and_Twelve-Month_2007_Financial_Results/</guid>
<description><![CDATA[Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline]]></title>
<link>http://www.worldpharmanews.net/Financial/EUSA_Pharma_Out-Licenses_Preclinical-Stage_Human_Antibody_to_GlaxoSmithKline/</link>
<comments>http://www.worldpharmanews.net/Financial/EUSA_Pharma_Out-Licenses_Preclinical-Stage_Human_Antibody_to_GlaxoSmithKline/</comments>
<pubDate>Tue, 19 Feb 2008 00:22:38 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/EUSA_Pharma_Out-Licenses_Preclinical-Stage_Human_Antibody_to_GlaxoSmithKline/</guid>
<description><![CDATA[EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rig<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GlaxoSmithKline buoyed by Buffett stake - Times Online]]></title>
<link>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_buoyed_by_Buffett_stake_-_Times_Online/</link>
<comments>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_buoyed_by_Buffett_stake_-_Times_Online/</comments>
<pubDate>Sat, 16 Feb 2008 01:24:54 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/GlaxoSmithKline_buoyed_by_Buffett_stake_-_Times_Online/</guid>
<description><![CDATA[GlaxoSmithKline shot on to the FTSE 100 leaderboard after Berkshire Hathaway, Warren Buffett's vehicle, revealed in a US Securities and Exchange Commission filing that it had bought 1.51 million Ame<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year]]></title>
<link>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Strong_Fourth_Quarter_to_Conclude_Outstanding_Year/</link>
<comments>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Strong_Fourth_Quarter_to_Conclude_Outstanding_Year/</comments>
<pubDate>Sat, 16 Feb 2008 01:24:54 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Genzyme_Delivers_Strong_Fourth_Quarter_to_Conclude_Outstanding_Year/</guid>
<description><![CDATA[Genzyme Corporation (NASDAQ: GENZ) today reported financial results for the full year and fourth quarter of 2007 and provided an outlook for continued strong growth in 2008 and beyond.<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement]]></title>
<link>http://www.worldpharmanews.net/Financial/Bayer_HealthCare_Affiliate_MEDRAD_and_Possis_Medical_Sign_Definitive_Merger_Agreement/</link>
<comments>http://www.worldpharmanews.net/Financial/Bayer_HealthCare_Affiliate_MEDRAD_and_Possis_Medical_Sign_Definitive_Merger_Agreement/</comments>
<pubDate>Sat, 16 Feb 2008 01:24:54 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Bayer_HealthCare_Affiliate_MEDRAD_and_Possis_Medical_Sign_Definitive_Merger_Agreement/</guid>
<description><![CDATA[Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered into a definitive merger agreement pursuant t<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Avista Capital Partners to Acquire Bristol-Myers Squibb Medical Imaging for $525 Million]]></title>
<link>http://www.worldpharmanews.net/Financial/Avista_Capital_Partners_to_Acquire_Bristol-Myers_Squibb_Medical_Imaging_for_525_Million/</link>
<comments>http://www.worldpharmanews.net/Financial/Avista_Capital_Partners_to_Acquire_Bristol-Myers_Squibb_Medical_Imaging_for_525_Million/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Avista_Capital_Partners_to_Acquire_Bristol-Myers_Squibb_Medical_Imaging_for_525_Million/</guid>
<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and Avista Capital Partners, a leading private equity firm, announced today the parties have signed a defini<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Adolor Enter into Exclusive Worldwide Collaboration]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_and_Adolor_Enter_into_Exclusive_Worldwide_Collaboration/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_and_Adolor_Enter_into_Exclusive_Worldwide_Collaboration/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:55 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_and_Adolor_Enter_into_Exclusive_Worldwide_Collaboration/</guid>
<description><![CDATA[Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Medarex Announces Completion of Sale of Shares in Genmab A/S]]></title>
<link>http://www.worldpharmanews.net/Financial/Medarex_Announces_Completion_of_Sale_of_Shares_in_Genmab_AS-1/</link>
<comments>http://www.worldpharmanews.net/Financial/Medarex_Announces_Completion_of_Sale_of_Shares_in_Genmab_AS-1/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Medarex_Announces_Completion_of_Sale_of_Shares_in_Genmab_AS-1/</guid>
<description><![CDATA[Medarex Announces Completion of Sale of Shares in Genmab A/SCNNMoney.com&amp;nbsp;- 3 hours ago... of the most advanced product candidates currently in P<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio]]></title>
<link>http://www.worldpharmanews.net/Financial/Novartis_achieves_record_results_in_2007_underscoring_benefits_of_strategic_healthcare_portfolio/</link>
<comments>http://www.worldpharmanews.net/Financial/Novartis_achieves_record_results_in_2007_underscoring_benefits_of_strategic_healthcare_portfolio/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Novartis_achieves_record_results_in_2007_underscoring_benefits_of_strategic_healthcare_portfolio/</guid>
<description><![CDATA[Novartis achieved record results for the total Group in 2007, with net sales rising 8% (+3% in local currencies) and net income advancing 66% to USD <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor]]></title>
<link>http://www.worldpharmanews.net/Financial/Pfizer_and_Scil_Finalize_Agreement_for_Novel_Cartilage_Growth_Factor/</link>
<comments>http://www.worldpharmanews.net/Financial/Pfizer_and_Scil_Finalize_Agreement_for_Novel_Cartilage_Growth_Factor/</comments>
<pubDate>Sat, 16 Feb 2008 01:21:22 CET</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Pfizer_and_Scil_Finalize_Agreement_for_Novel_Cartilage_Growth_Factor/</guid>
<description><![CDATA[Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil's cartilage specific grow<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
